Heidi Martini-Stoica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heidi Martini-Stoica has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Adam J. Kimple
Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA
2 shared publicationsBrian D. Thorp
Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA
2 shared publicationsBrittany T. Rupp
Department of Oral and Craniofacial Molecular Biology Virginia Commonwealth University Richmond Virginia USA
2 shared publicationsCharles S. Ebert
Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA
2 shared publicationsFrederic Askin
Department of Pathology and Laboratory Medicine University of North Carolina School of Medicine Chapel Hill North Carolina USA
2 shared publicationsHong Dang
Marsico Lung Institute University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Wiley in International Forum of Allergy & Rhinology
A Single‐Cell Atlas of Juvenile Nasopharyngeal Angiofibroma Identifies Endothelial Remodeling and Candidate VEGF‐Pathway Targets
Background: Juvenile nasopharyngeal angiofibroma (JNA) is a rare locally aggressive vascular sinonasal tumor that primarily affects adolescent males. Despite advances in endoscopic surgery and preoperative embolization, JNA can be associated with major operative bleeding risk and clinically meaningful recurrence, while non‐surgical treatment options remain limited. Methods: To define the cellular programs underlying JNA vascularity, we performed single‐cell RNA sequencing of post‐embolization JNA tumors ( n = 2), tumor‐adjacent mucosa, and control sinonasal tissue. We analyzed cell composition, differential gene expression, pathway enrichment, and cell–cell communication, followed by Drug2cell‐based mapping of transcriptional states to candidate therapeutic targets. Results: JNA contained an expanded fibrovascular compartment composed of endothelial cells, fibroblasts, pericytes, vascular smooth muscle cells, and neuronal‐like cells. Neuronal‐like cells were enriched in JNA but showed relatively limited transcriptional differences from tumor‐adjacent tissue. By contrast, endothelial cells demonstrated the strongest disease‐associated remodeling, with enrichment of angiogenesis, extracellular matrix organization, hypoxia response, and cell migration pathways. Endothelial cells also showed downregulation of adaptive immune signaling pathways, suggesting reduced immune engagement within the tumor microenvironment. Intercellular communication analyses revealed dense endothelial‐stromal signaling across the JNA fibrovascular network. Drug2cell analysis nominated VEGF/VEGFR signaling as a candidate drug target, with VEGFR‐inhibiting agents predicted to act primarily on endothelial populations. Conclusions: JNA is organized around an angiogenesis‐dominant fibrovascular program driven by endothelial‐centered signaling. These data support further investigation of VEGF/VEGFR‐directed inhibition as a potential adjunctive strategy for patients with recurrent, unresectable, or surgically high‐risk JNA.
- 17 November 2026
- Published by Wiley in International Forum of Allergy & Rhinology
Open AccessA Single‐Cell Atlas of Juvenile Nasopharyngeal Angiofibroma Identifies Endothelial Remodeling and Candidate VEGF‐Pathway Targets
Background: Juvenile nasopharyngeal angiofibroma (JNA) is a rare locally aggressive vascular sinonasal tumor that primarily affects adolescent males. Despite advances in endoscopic surgery and preoperative embolization, JNA can be associated with major operative bleeding risk and clinically meaningful recurrence, while non‐surgical treatment options remain limited. Methods: To define the cellular programs underlying JNA vascularity, we performed single‐cell RNA sequencing of post‐embolization JNA tumors ( n = 2), tumor‐adjacent mucosa, and control sinonasal tissue. We analyzed cell composition, differential gene expression, pathway enrichment, and cell–cell communication, followed by Drug2cell‐based mapping of transcriptional states to candidate therapeutic targets. Results: JNA contained an expanded fibrovascular compartment composed of endothelial cells, fibroblasts, pericytes, vascular smooth muscle cells, and neuronal‐like cells. Neuronal‐like cells were enriched in JNA but showed relatively limited transcriptional differences from tumor‐adjacent tissue. By contrast, endothelial cells demonstrated the strongest disease‐associated remodeling, with enrichment of angiogenesis, extracellular matrix organization, hypoxia response, and cell migration pathways. Endothelial cells also showed downregulation of adaptive immune signaling pathways, suggesting reduced immune engagement within the tumor microenvironment. Intercellular communication analyses revealed dense endothelial‐stromal signaling across the JNA fibrovascular network. Drug2cell analysis nominated VEGF/VEGFR signaling as a candidate drug target, with VEGFR‐inhibiting agents predicted to act primarily on endothelial populations. Conclusions: JNA is organized around an angiogenesis‐dominant fibrovascular program driven by endothelial‐centered signaling. These data support further investigation of VEGF/VEGFR‐directed inhibition as a potential adjunctive strategy for patients with recurrent, unresectable, or surgically high‐risk JNA.
- Open Access
A Single-cell Atlas of Juvenile Nasopharyngeal Angiofibroma Reveals VEGF-Driven Angiogenic Remodeling as a Therapeutic Vulnerability
Background: Juvenile nasopharyngeal angiofibroma (JNA) is a rare locally aggressive vascular sinonasal tumor that primarily affects adolescent males. Despite advances in endoscopic surgery and preoperative embolization, JNA can be associated with major operative bleeding risk and clinically meaningful recurrence, while non-surgical treatment options remain limited. Methods: To define the cellular programs underlying JNA vascularity, we performed single-cell RNA sequencing of JNA tumors (n=2), tumor-adjacent mucosa, and control sinonasal tissue. We analyzed cell composition, differential gene expression, pathway enrichment, and cell–cell communication, followed by Drug2cell-based mapping of transcriptional states to candidate therapeutic targets. Results: JNA contained an expanded fibrovascular compartment composed of endothelial cells, fibroblasts, pericytes, vascular smooth muscle cells, and neural crest–like cells. Neural crest–like cells were enriched in JNA but showed relatively limited transcriptional differences from tumor-adjacent tissue. By contrast, endothelial cells demonstrated the strongest disease-associated remodeling, with enrichment of angiogenesis, extracellular matrix organization, hypoxia response, and cell migration pathways. Endothelial cells also showed downregulation of adaptive immune signaling pathways, suggesting reduced immune engagement within the tumor microenvironment. Intercellular communication analyses revealed dense endothelial–stromal signaling across the JNA fibrovascular network. Drug2cell analysis nominated VEGF/VEGFR signaling as a candidate therapeutic vulnerability, with VEGFR-targeting agents predicted to act primarily on vascular and lymphatic endothelial populations. Conclusions: JNA is organized around an angiogenesis-dominant fibrovascular program driven by endothelial-centered signaling. These data support further investigation of VEGF/VEGFR-directed therapy as a potential adjunctive strategy for patients with recurrent, unresectable, or surgically high-risk JNA.
Open AccessA Single-cell Atlas of Juvenile Nasopharyngeal Angiofibroma Reveals VEGF-Driven Angiogenic Remodeling as a Therapeutic Vulnerability
Background: Juvenile nasopharyngeal angiofibroma (JNA) is a rare locally aggressive vascular sinonasal tumor that primarily affects adolescent males. Despite advances in endoscopic surgery and preoperative embolization, JNA can be associated with major operative bleeding risk and clinically meaningful recurrence, while non-surgical treatment options remain limited. Methods: To define the cellular programs underlying JNA vascularity, we performed single-cell RNA sequencing of JNA tumors (n=2), tumor-adjacent mucosa, and control sinonasal tissue. We analyzed cell composition, differential gene expression, pathway enrichment, and cell–cell communication, followed by Drug2cell-based mapping of transcriptional states to candidate therapeutic targets. Results: JNA contained an expanded fibrovascular compartment composed of endothelial cells, fibroblasts, pericytes, vascular smooth muscle cells, and neural crest–like cells. Neural crest–like cells were enriched in JNA but showed relatively limited transcriptional differences from tumor-adjacent tissue. By contrast, endothelial cells demonstrated the strongest disease-associated remodeling, with enrichment of angiogenesis, extracellular matrix organization, hypoxia response, and cell migration pathways. Endothelial cells also showed downregulation of adaptive immune signaling pathways, suggesting reduced immune engagement within the tumor microenvironment. Intercellular communication analyses revealed dense endothelial–stromal signaling across the JNA fibrovascular network. Drug2cell analysis nominated VEGF/VEGFR signaling as a candidate therapeutic vulnerability, with VEGFR-targeting agents predicted to act primarily on vascular and lymphatic endothelial populations. Conclusions: JNA is organized around an angiogenesis-dominant fibrovascular program driven by endothelial-centered signaling. These data support further investigation of VEGF/VEGFR-directed therapy as a potential adjunctive strategy for patients with recurrent, unresectable, or surgically high-risk JNA.
- 20 November 2023
- Published by Springer Nature in Nature Neuroscience
- Vol. 27 (1) , 48-62
TFEB–vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy
Transcription factor EB (TFEB) mediates gene expression through binding to the coordinated lysosome expression and regulation (CLEAR) sequence. TFEB targets include subunits of the vacuolar ATPase (v-ATPase), which are essential for lysosome acidification. Single-nucleus RNA sequencing of wild-type and PS19 (Tau) transgenic mice expressing the P301S mutant tau identified three unique microglia subclusters in Tau mice that were associated with heightened lysosome and immune pathway genes. To explore the lysosome–immune relationship, we specifically disrupted the TFEB–v-ATPase signaling by creating a knock-in mouse line in which the CLEAR sequence of one of the v-ATPase subunits, Atp6v1h, was mutated. CLEAR mutant exhibited a muted response to TFEB, resulting in impaired lysosomal acidification and activity. Crossing the CLEAR mutant with Tau mice led to higher tau pathology but diminished microglia response. These microglia were enriched in a subcluster low in mTOR and HIF-1 pathways and were locked in a homeostatic state. Our studies demonstrate a physiological function of TFEB–v-ATPase signaling in maintaining lysosomal homeostasis and a critical role of the lysosome in mounting a microglia and immune response in tauopathy and Alzheimer’s disease.
- 20 November 2023
- Published by Springer Nature in Nature Neuroscience
- Vol. 27 (1) , 48-62
TFEB–vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy
Transcription factor EB (TFEB) mediates gene expression through binding to the coordinated lysosome expression and regulation (CLEAR) sequence. TFEB targets include subunits of the vacuolar ATPase (v-ATPase), which are essential for lysosome acidification. Single-nucleus RNA sequencing of wild-type and PS19 (Tau) transgenic mice expressing the P301S mutant tau identified three unique microglia subclusters in Tau mice that were associated with heightened lysosome and immune pathway genes. To explore the lysosome–immune relationship, we specifically disrupted the TFEB–v-ATPase signaling by creating a knock-in mouse line in which the CLEAR sequence of one of the v-ATPase subunits, Atp6v1h, was mutated. CLEAR mutant exhibited a muted response to TFEB, resulting in impaired lysosomal acidification and activity. Crossing the CLEAR mutant with Tau mice led to higher tau pathology but diminished microglia response. These microglia were enriched in a subcluster low in mTOR and HIF-1 pathways and were locked in a homeostatic state. Our studies demonstrate a physiological function of TFEB–v-ATPase signaling in maintaining lysosomal homeostasis and a critical role of the lysosome in mounting a microglia and immune response in tauopathy and Alzheimer’s disease.